CVTX CV Therapeutics (MM)

CV Therapeutics Announces Five Abstracts Accepted for Presentation at American College of Cardiology Scientific Sessions 2004 PALO ALTO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced that five abstracts, featuring studies of ranolazine and regadenoson (CVT-3146), and data from patients with chronic angina, have been accepted for presentation at the American College of Cardiology (ACC) Scientific Sessions 2004, taking place in New Orleans, LA from March 7-10, 2004. Accepted abstracts include: Ranolazine -- Ranolazine Attenuates Increased Variability of Action Potential Duration and After Depolarizations Caused by Augmentation of Late Sodium Current -- Yejia Song, Lin Wu, John C. Shryock, Luiz Belardinelli. Monday, March 8, 2004 from 4:00 p.m. to 5:00 p.m. Central Time (CT), Ernest N. Morial Convention Center, Hall G. Presentation #1110-213. -- Ranolazine Inhibits Late Sodium Current in Isolated Left Ventricular Myocytes of Dogs With Heart Failure -- Albertas I. Undrovinas, Nidas A. Undrovinas, Luiz Belardinelli, Hani N. Sabbah. Monday, March 8, 2004 from 9:00 a.m. to 10:00 a.m. CT, Ernest N. Morial Convention Center, Hall G. Presentation # 1068-128. Chronic Angina -- Symptoms Persist in Patients With Chronic Angina Despite Frequent Anti-Anginal Use and Prior Revascularization -- George Vetrovec, Jennifer Watson, Bernard Chaitman, Robert Cody, Nanette Wenger. Monday, March 8, 2004from 3:00 p.m. to 4:00 p.m. CT, Ernest N. Morial Convention Center, Hall G. Presentation #1099-87. Regadenoson (CVT-3146) -- Differential Vasodilatory Effects of CVT-3146, an A2A Adenosine Receptor Agonist, in Various Vascular Beds in Anesthetized Dogs -- Arvinder K. Dhalla, Jiang Xu, William Kussmaul, Peter P. Kurnik, Amir Pelleg, Luiz Belardinelli. Tuesday, March 9, 2004 from 4:00 p.m. to 5:00 p.m. CT, Ernest N. Morial Convention Center, Hall G. Presentation #1170-142. -- Initial Results Regarding the Safety, Tolerability, and Hemodynamic Effects of CVT-3146, a Selective Adenosine A2A Agonist, in Patients Undergoing Pharmacologic Stress SPECT Myocardial Perfusion Imaging -- Robert C. Hendel, John J. Mahmarian, Timothy M. Bateman, Manuel D. Cerqueira, Ami E. Iskandrian, Markus Jerling, Hisham Y. Abdallah, Jeffrey A. Leppo. Tuesday, March 9, 2004 from 4:00 p.m. to 5:00 p.m. CT, Ernest N. Morial Convention Center, Hall G. Presentation #1170-141. Additional information regarding the ACC Scientific Sessions 2004 can be accessed at http://www.acc.org/2004ann_meeting/home/home.htm. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has four compounds in clinicaldevelopment. If approved by the FDA, Ranexa would represent the first new class of anti-anginal therapy in more than 25 years. Regadenoson (CVT-3146), a selective A2A-adenosine receptor agonist, is being developed for potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Tecadenoson, an A1-adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. Adentri(TM), an A1-adenosine receptor antagonist for the potential treatment of acute and chronic congestive heart failure, is licensed to Biogen, Inc. (now Biogen Idec, Inc.). For more information, please visit CV Therapeutics' website at http://www.cvt.com/. CV Therapeutics is a development-stage company. None of the company's products have been approved for marketing by the FDA or any foreign regulatory authorities. Any products of the company discussed here are currently under investigation in clinical trials subject to United States Investigational New Drug applications, and as applicable, appropriate clinical trial applications to regulatory authorities outside the United States. Except for the historical information contained herein, the matters set forth in this press release, including statements asto development and commercialization of the company's products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; the timing of clinical trials; the dependence on collaborative and licensing agreements; commercialization of our products; and other risks detailed from time to time in CVT's SEC reports, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. CVT disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: CV Therapeutics. Inc. CONTACT: investors, Dan Spiegelman, SVP & Chief Financial Officer, +1-650-384-8509, or Christopher Chai, Treasurer & Executive Director, Investor Relations, +1-650-384-8560, or media, John Bluth, Director, Corporate Communications, +1-650-384-8850, all of CV Therapeutics, Inc.; or Carol Harrison of Fleishman-Hillard, +1-212-453-2442, for CV Therapeutics, Inc. Web site: http://www.cvt.com/

Copyright